Search PubMedSearch

PubMed · 42698661

Assessing the genetic potential of a milk mid-infrared prediction of heat stress response in dairy cows using a temperature-humidity index-independent approach.

Abstract

Selection for heat tolerance remains challenging due to the difficulty of accessing reliable phenotypes at large scale. An alternative could be established using mid-infrared spectra, which are collected routinely through milk recording, and have already shown their value as proxies for a variety of phenotypes that are costly or difficult to measure. Recently, a first prediction of heat stress response in dairy cows based solely on milk mid-infrared spectra was developed. This prediction was obtained using models calibrated on surface body temperature and milk composition variations. Its potential as a detection tool was explored, but no genetic analyses has been performed. On this basis, the objectives of this study were to estimate the heritability of the predicted heat stress response, assess its genetic correlations with traits from the Walloon official genetic evaluation, and identify genomic regions associated with heat tolerance through a GWAS, all without using temperature-humidity index (THI) information. The estimated heritability (0.10) was low but sufficient to enable genetic selection and consistent with expectations for a heat stress-related trait. Also as expected, an antagonistic relationship between heat tolerance and milk production was observed, but its extent was notably reduced compared with traditional approaches. In addition, genetic correlations with other traits were neutral (fat yield) or favorable (protein yield, SCS, fertility, longevity). Concerning the GWAS, genomic regions and candidate genes previously associated with the response to heat stress were highlighted, as well as others related to energy balance maintenance. Overall, these results support the relevance of the prediction for the heat stress response as a new phenotype for heat tolerance selection that does not require any THI information. They also reinforce the importance of energy balance for dairy cows to cope with heat stress.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P Lemal, K Wijnrocx, H Soyeurt, M Schroyen, N Gengler. 2026-06-11. Assessing the genetic potential of a milk mid-infrared prediction of heat stress response in dairy cows using a temperature-humidity index-independent approach.. https://doi.org/10.3168/jdsc.2026-1053

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article